TY - JOUR
T1 - Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
AU - Bolli, Niccolo
AU - Avet-Loiseau, Hervé
AU - Wedge, David C.
AU - Van Loo, Peter
AU - Alexandrov, Ludmil B.
AU - Martincorena, Inigo
AU - Dawson, Kevin J.
AU - Iorio, Francesco
AU - Nik-Zainal, Serena
AU - Bignell, Graham R.
AU - Hinton, Jonathan W.
AU - Li, Yilong
AU - Tubio, Jose M C
AU - McLaren, Stuart
AU - O'Meara, Sarah
AU - Butler, Adam P.
AU - Teague, Jon W.
AU - Mudie, Laura
AU - Anderson, Elizabeth
AU - Rashid, Naim
AU - Tai, Yu Tzu
AU - Shammas, Masood A.
AU - Sperling, Adam S.
AU - Fulciniti, Mariateresa
AU - Richardson, Paul G.
AU - Parmigiani, Giovanni
AU - Magrangeas, Florence
AU - Minvielle, Stephane
AU - Moreau, Philippe
AU - Attal, Michel
AU - Facon, Thierry
AU - Futreal, P. Andrew
AU - Anderson, Kenneth C.
AU - Campbell, Peter J.
AU - Munshi, Nikhil C.
PY - 2014/1/16
Y1 - 2014/1/16
N2 - Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex subclonal structure and show clusters of subclonal variants, including subclonal driver mutations. Serial sampling reveals diverse patterns of clonal evolution, including linear evolution, differential clonal response and branching evolution. Diverse processes contribute to the mutational repertoire, including kataegis and somatic hypermutation, and their relative contribution changes over time. We find heterogeneity of mutational spectrum across samples, with few recurrent genes. We identify new candidate genes, including truncations of SP140, LTB, ROBO1 and clustered missense mutations in EGR1. The myeloma genome is heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics of evolution, which may impact prognostic stratification, therapeutic approaches and assessment of disease response to treatment.
AB - Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex subclonal structure and show clusters of subclonal variants, including subclonal driver mutations. Serial sampling reveals diverse patterns of clonal evolution, including linear evolution, differential clonal response and branching evolution. Diverse processes contribute to the mutational repertoire, including kataegis and somatic hypermutation, and their relative contribution changes over time. We find heterogeneity of mutational spectrum across samples, with few recurrent genes. We identify new candidate genes, including truncations of SP140, LTB, ROBO1 and clustered missense mutations in EGR1. The myeloma genome is heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics of evolution, which may impact prognostic stratification, therapeutic approaches and assessment of disease response to treatment.
UR - http://www.scopus.com/inward/record.url?scp=84892699941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892699941&partnerID=8YFLogxK
U2 - 10.1038/ncomms3997
DO - 10.1038/ncomms3997
M3 - Article
C2 - 24429703
AN - SCOPUS:84892699941
SN - 2041-1723
VL - 5
JO - Nature Communications
JF - Nature Communications
M1 - 2997
ER -